TNXP.OQ
Latest Trade
1.04USDChange
0.01(+0.49%)Volume
605,940Today's Range
-
1.0452 Week Range
-
2.46As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 1.03 |
|---|---|
Open | 1.02 |
Volume | 605,940 |
3M AVG Volume | 678.00 |
Today's High | 1.04 |
Today's Low | 1.01 |
52 Week High | 2.46 |
52 Week Low | 0.51 |
Shares Out (MIL) | 323.92 |
Market Cap (MIL) | 332.02 |
Forward P/E | -4.90 |
Dividend (Yield %) | -- |
Tonix Pharmaceuticals Enters Into Exclusive Worldwide Licensing Agreement With Oyagen To Develop Antiviral Sars-Cov-2 Inhibitor, TNX-3500, For Treatment Of Covid-19
Tonix Pharma Says Data Shows TNX-1800 Induces Protection Against SARS-COV-2 Infection In Non-Human Primates
Tonix Pharmaceuticals Reports Q4 Loss Per Share Of $0.10
Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
Industry
Biotechnology & Drugs
Contact Info
26 MAIN STREET, SUITE 101
CHATHAM, NJ
07928
United States
+1.212.9809155
https://www.tonixpharma.com/Executive Leadership
Seth Lederman
Chairman of the Board, President, Chief Executive Officer
Bradley Saenger
Chief Financial Officer, Treasurer
Jessica Edgar Morris
Chief Operating Officer
Herbert W. Harris
Executive Vice President - Translational Medicine
Gregory M. Sullivan
Secretary, Chief Medical Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 2.41 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -103.21 |
Return on Equity (TTM) | -89.52 |
* TONIX PHARMACEUTICALS PLANS MASSACHUSETTS RESEARCH AND DEVELOPMENT FACILITY TO ACCELERATE CLINICAL DEVELOPMENT OF VACCINES AND PROTEIN-BASED THERAPEUTICS
* TONIX PHARMACEUTICALS ANNOUNCES ENROLLMENT OF PHASE 3 RELIEF TRIAL OF TNX-102 SL FOR MANAGEMENT OF FIBROMYALGIA IS AHEAD OF SCHEDULE
* TONIX PHARMACEUTICALS AND SOUTHERN RESEARCH ANNOUNCE EXPANSION OF COVID-19 VACCINE COLLABORATION
* TONIX PHARMACEUTICALS ANNOUNCES APPOINTMENT OF RICHARD H. BAGGER TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* TONIX PHARMACEUTICALS ANNOUNCES FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO BE MANUFACTURING PARTNER FOR COVID-19 VACCINE CANDIDATE TNX-1800 Source text for Eikon: Further company coverage:
* TONIX PHARMACEUTICALS POSTED RESULTS FROM PHARMACOKINETIC ANALYSES OF TNX-102 SL AND TNX-601 CR IN ADVANCE OF VIRTUAL POSTER PRESENTATIONS AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com...
* TONIX PHARMACEUTICALS - WILL PRESENT CERTAIN INFORMATION REGARDING ITS VACCINE CANDIDATES TARGETING COVID-19 AT A PANEL ON MAY 19 Source text: (https://bit.ly/3fURWwv) Further company coverage:
* TONIX PHARMACEUTICALS - U.S. FDA INFORMED CO THAT BREAKTHROUGH THERAPY DESIGNATION WAS RESCINDED FOR TNX-102 SL FOR POST-TRAUMATIC STRESS DISORDER TREATMENT Source text for Eikon: https://bit.ly/2L8YrOe Further company coverage:
* TONIX PHARMACEUTICALS ENTERS INTO RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA TO DEVELOP NOVEL HORSEPOX-BASED VACCINES, TNX-1810, TNX-1820 AND TNX-1830, FOR THE PREVENTION OF COVID-19
* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 RELIEF STUDY OF TNX-102 SL (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR MANAGEMENT OF FIBROMYALGIA
* TONIX PHARMACEUTICALS HOLDING CORP FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text: (https://bit.ly/2Xp9gD9) Further company coverage:
* ENTERED INTO A SALES AGREEMENT WITH A.G.P./ALLIANCE GLOBAL PARTNERS
* TONIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
* TONIX PHARMACEUTICALS, INC. PRICES $16,005,000 COMMON STOCK OFFERING PRICED AT-THE-MARKET
* TONIX PHARMACEUTICALS PRICES $7.5 MILLION PUBLIC OFFERING Source text for Eikon: Further company coverage:
* TONIX PHARMACEUTICALS HOLDING CORP SAYS ON MAY 1, CO ENTERED INTO SALES AGREEMENT WITH COWEN AND CO RELATING TO SHARES OF CO'S COMMON STOCK OFFERED
* TONIX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE
* TONIX PHARMACEUTICALS HOLDING CORP QTRLY NET LOSS PER COMMON SHARE $0.88 Source text: (https://bit.ly/2G8HkXY) Further company coverage:
* TONIX PHARMACEUTICALS HOLDING SAYS FILES FOR MIXED SHELF OF UP TO $75 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2KqLRZ4) Further company coverage:
* TONIX PHARMACEUTICALS RECEIVES IND CLEARANCE BY U.S. FDA FOR TNX-102 SL IN AGITATION IN ALZHEIMER’S DISEASE Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.